Iktos vs Insilico Medicine (2026)
Two generative chemistry companies with different commercial shapes and different distances travelled. Insilico has the cleanest end to end story in this category: its target engine picked the target, its generative engine designed the molecule, the discovery was published in peer reviewed literature and the lead asset carries orphan drug designation. Iktos has been doing generative medicinal chemistry since 2016 and sells both ways, as licensed software and as a discovery collaboration, which matters because most partnerships in this field stall when the customer wants the work in house. Insilico is the stronger evidence. Iktos is the easier relationship to enter and leave. Hold the conflict in mind either way: the company that picks the target also reports the result.
- One engine prioritised the target, another generated the molecule, and the resulting drug reached the clinic, with the discovery published in peer reviewed literature.
- Orphan drug designation on a lead asset is a real external checkpoint rather than a platform description.
- The platform is sold as software as well as run internally, so a customer can license the tools rather than only partner.
- It sells both as licensed software and as a discovery collaboration, giving a pharmaceutical team a route in that does not require handing over the programme.
- Nearly a decade of operating history in generative medicinal chemistry means the workflow has met real programmes rather than benchmark tasks.
- The dual model provides an exit from a services relationship into a licence, which is rare in this category.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Iktos and Insilico Medicine are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Iktos | Insilico Medicine |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2016 | 2014 |
| Headquarters | Paris, France | Cambridge, Massachusetts |
| Website | iktos.ai | insilico.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Iktos its top capability grade on AI Centrality and Deployment Model and Data Residency. Set against Insilico Medicine, Iktos grades higher on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and AI Governance and Bias Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Insilico Medicine its top capability grade on AI Centrality, Clinical and Operational Evidence and FDA and Regulatory Status. Set against Iktos, Insilico Medicine grades higher on Clinical and Operational Evidence and FDA and Regulatory Status. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Iktos or Insilico Medicine?
On the axes where the AI Health Index separates them, Iktos grades higher on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and AI Governance and Bias Disclosure, and Insilico Medicine grades higher on Clinical and Operational Evidence and FDA and Regulatory Status. Iktos leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Iktos and Insilico Medicine differ most?
The widest separation the AI Health Index records between Iktos and Insilico Medicine is on Clinical and Operational Evidence, where Iktos grades C and Insilico Medicine grades A. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Iktos and Insilico Medicine grade the same?
The AI Health Index grades Iktos and Insilico Medicine the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
One company is simultaneously a platform vendor and a clinical stage biotech, which is the structural conflict to hold while reading its evidence, since the same organisation selects the target, designs the molecule, runs the analysis and reports the result. Neither holds a located security attestation and neither publishes pricing. A clinical stage asset says one molecule reached humans rather than that the platform generalises, and neither company publishes what proportion of its designs failed before the ones you hear about.